Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung

Chih Cheng Hsieh, Kuan Chih Chow, Huei J. Fahn, Chun Ming Tsai, Wing Y. Li, Min Hsiung Huang, Liang Shun Wang

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Background. Even with early diagnosis and adequate resection, the 5- year survival rate for stage I lung cancer patients is around 60% to 70%. Overexpression of HER-2/neu protein is associated with poor prognosis in lung cancers. In this study, we evaluated the expression of HER-2/neu in cancer cells of lung and assessed their clinicopathologic and prognostic significance. Methods. From 1986 to 1995, clinical data on 42 consecutive patients who underwent complete surgical resection for stage I lung adenocarcinoma were collected. Expression of HER-2/neu in paraffin-embedded tumor samples was determined by immunohistochemistry and scored with a semiquantitative method. Results. Twenty-one of 42 patients were positive for HER-2/neu overexpression in tumor. Compared with patients with low HER-2/neu expression, patients with HER-2/neu overexpression had a significantly higher incidence of early tumor recurrence (p = 0.014). Survival was also significantly better in patients without HER-2/-neu overexpression than in those with HER-2/neu overexpression (p = 0.0047). By univariate analysis, HER-2/neu overexpression and poor cell differentiation are two important factors correlated with poor prognosis. Conclusions. Expression of HER-2/neu oncoprotein in stage I lung adenocarcinoma can predict the tumor's aggressiveness. Early tumor recurrence was frequently detected in patients with HER-2/neu overexpression. We recommend an individualized therapeutic strategy based on the level of HER-2/neu oncoprotein in the tumor cells.

Original languageEnglish
Pages (from-to)1159-1164
Number of pages6
JournalAnnals of Thoracic Surgery
Volume66
Issue number4
DOIs
Publication statusPublished - Oct 1998
Externally publishedYes

Fingerprint

Lung Neoplasms
Neoplasms
Oncogene Proteins
Recurrence
Adenocarcinoma of lung
Paraffin
Early Diagnosis
Cell Differentiation
Survival Rate
Immunohistochemistry
Survival
Incidence
Proteins
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Hsieh, C. C., Chow, K. C., Fahn, H. J., Tsai, C. M., Li, W. Y., Huang, M. H., & Wang, L. S. (1998). Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. Annals of Thoracic Surgery, 66(4), 1159-1164. https://doi.org/10.1016/S0003-4975(98)00792-9

Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. / Hsieh, Chih Cheng; Chow, Kuan Chih; Fahn, Huei J.; Tsai, Chun Ming; Li, Wing Y.; Huang, Min Hsiung; Wang, Liang Shun.

In: Annals of Thoracic Surgery, Vol. 66, No. 4, 10.1998, p. 1159-1164.

Research output: Contribution to journalArticle

Hsieh, CC, Chow, KC, Fahn, HJ, Tsai, CM, Li, WY, Huang, MH & Wang, LS 1998, 'Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung', Annals of Thoracic Surgery, vol. 66, no. 4, pp. 1159-1164. https://doi.org/10.1016/S0003-4975(98)00792-9
Hsieh, Chih Cheng ; Chow, Kuan Chih ; Fahn, Huei J. ; Tsai, Chun Ming ; Li, Wing Y. ; Huang, Min Hsiung ; Wang, Liang Shun. / Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. In: Annals of Thoracic Surgery. 1998 ; Vol. 66, No. 4. pp. 1159-1164.
@article{0ac4a0bb2e4548709dff9ac88582a7f2,
title = "Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung",
abstract = "Background. Even with early diagnosis and adequate resection, the 5- year survival rate for stage I lung cancer patients is around 60{\%} to 70{\%}. Overexpression of HER-2/neu protein is associated with poor prognosis in lung cancers. In this study, we evaluated the expression of HER-2/neu in cancer cells of lung and assessed their clinicopathologic and prognostic significance. Methods. From 1986 to 1995, clinical data on 42 consecutive patients who underwent complete surgical resection for stage I lung adenocarcinoma were collected. Expression of HER-2/neu in paraffin-embedded tumor samples was determined by immunohistochemistry and scored with a semiquantitative method. Results. Twenty-one of 42 patients were positive for HER-2/neu overexpression in tumor. Compared with patients with low HER-2/neu expression, patients with HER-2/neu overexpression had a significantly higher incidence of early tumor recurrence (p = 0.014). Survival was also significantly better in patients without HER-2/-neu overexpression than in those with HER-2/neu overexpression (p = 0.0047). By univariate analysis, HER-2/neu overexpression and poor cell differentiation are two important factors correlated with poor prognosis. Conclusions. Expression of HER-2/neu oncoprotein in stage I lung adenocarcinoma can predict the tumor's aggressiveness. Early tumor recurrence was frequently detected in patients with HER-2/neu overexpression. We recommend an individualized therapeutic strategy based on the level of HER-2/neu oncoprotein in the tumor cells.",
author = "Hsieh, {Chih Cheng} and Chow, {Kuan Chih} and Fahn, {Huei J.} and Tsai, {Chun Ming} and Li, {Wing Y.} and Huang, {Min Hsiung} and Wang, {Liang Shun}",
year = "1998",
month = "10",
doi = "10.1016/S0003-4975(98)00792-9",
language = "English",
volume = "66",
pages = "1159--1164",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "4",

}

TY - JOUR

T1 - Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung

AU - Hsieh, Chih Cheng

AU - Chow, Kuan Chih

AU - Fahn, Huei J.

AU - Tsai, Chun Ming

AU - Li, Wing Y.

AU - Huang, Min Hsiung

AU - Wang, Liang Shun

PY - 1998/10

Y1 - 1998/10

N2 - Background. Even with early diagnosis and adequate resection, the 5- year survival rate for stage I lung cancer patients is around 60% to 70%. Overexpression of HER-2/neu protein is associated with poor prognosis in lung cancers. In this study, we evaluated the expression of HER-2/neu in cancer cells of lung and assessed their clinicopathologic and prognostic significance. Methods. From 1986 to 1995, clinical data on 42 consecutive patients who underwent complete surgical resection for stage I lung adenocarcinoma were collected. Expression of HER-2/neu in paraffin-embedded tumor samples was determined by immunohistochemistry and scored with a semiquantitative method. Results. Twenty-one of 42 patients were positive for HER-2/neu overexpression in tumor. Compared with patients with low HER-2/neu expression, patients with HER-2/neu overexpression had a significantly higher incidence of early tumor recurrence (p = 0.014). Survival was also significantly better in patients without HER-2/-neu overexpression than in those with HER-2/neu overexpression (p = 0.0047). By univariate analysis, HER-2/neu overexpression and poor cell differentiation are two important factors correlated with poor prognosis. Conclusions. Expression of HER-2/neu oncoprotein in stage I lung adenocarcinoma can predict the tumor's aggressiveness. Early tumor recurrence was frequently detected in patients with HER-2/neu overexpression. We recommend an individualized therapeutic strategy based on the level of HER-2/neu oncoprotein in the tumor cells.

AB - Background. Even with early diagnosis and adequate resection, the 5- year survival rate for stage I lung cancer patients is around 60% to 70%. Overexpression of HER-2/neu protein is associated with poor prognosis in lung cancers. In this study, we evaluated the expression of HER-2/neu in cancer cells of lung and assessed their clinicopathologic and prognostic significance. Methods. From 1986 to 1995, clinical data on 42 consecutive patients who underwent complete surgical resection for stage I lung adenocarcinoma were collected. Expression of HER-2/neu in paraffin-embedded tumor samples was determined by immunohistochemistry and scored with a semiquantitative method. Results. Twenty-one of 42 patients were positive for HER-2/neu overexpression in tumor. Compared with patients with low HER-2/neu expression, patients with HER-2/neu overexpression had a significantly higher incidence of early tumor recurrence (p = 0.014). Survival was also significantly better in patients without HER-2/-neu overexpression than in those with HER-2/neu overexpression (p = 0.0047). By univariate analysis, HER-2/neu overexpression and poor cell differentiation are two important factors correlated with poor prognosis. Conclusions. Expression of HER-2/neu oncoprotein in stage I lung adenocarcinoma can predict the tumor's aggressiveness. Early tumor recurrence was frequently detected in patients with HER-2/neu overexpression. We recommend an individualized therapeutic strategy based on the level of HER-2/neu oncoprotein in the tumor cells.

UR - http://www.scopus.com/inward/record.url?scp=0032191181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032191181&partnerID=8YFLogxK

U2 - 10.1016/S0003-4975(98)00792-9

DO - 10.1016/S0003-4975(98)00792-9

M3 - Article

C2 - 9800799

AN - SCOPUS:0032191181

VL - 66

SP - 1159

EP - 1164

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 4

ER -